Clinical trials: Multiple Sclerosis - Relapsing Remitting
Relapsing Remitting Multiple Sclerosis RRMS
A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®
This was a 3-year, prospective, multi-center, open-label study to describe the long term changes of optical coherence tomography (OCT) parameters in RRMS patients under treatment with Fingolimod.
- Trial name
- PASSOS (NCT01705236)
- Testing
- Fingolimod
- Where
- 10 sites in Germany, Switzerland
- Volunteers
- 87 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple sclerosis (RRMS) and to assess the pharmacokinetics (PK) of BIIB017 in pediatric…
- Trial name
- NCT03958877
- Testing
- BIIB017 (peginterferon beta-1a), Interferon beta type 1a
- Where
- 65 sites in United States, Argentina and 20 more
- Volunteers
- 152 people
- Sponsor
- Biogen
Multiple Sclerosis, Acute Relapsing
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
This is a Phase 1, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study in subjects with relapsing Multiple Sclerosis (MS).
- Trial name
- NCT02398461
- Testing
- rHIgM22
- Where
- 12 sites in United States
- Volunteers
- 27 people
- Sponsor
- Acorda Therapeutics
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis
General Note: throughout this record, "Rebif® New Formulation" is used for historical and consistency purposes. Objectives: Primary: To evaluate the efficacy of Rebif® New Formulation (Interferon-beta-1a [IFN-beta-1a], RNF)…
- Trial name
- IMPROVE (NCT00441103)
- Testing
- Rebif® New Formulation (IFN-beta-1a, RNF)
- Volunteers
- 180 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing Remitting Multiple Sclerosis
An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease
This is a multinational, multicenter, randomized, double-blind, parallel-group active extension of LAQ/5062 study (NCT00349193), assessing the tolerability, safety and efficacy of two doses (0.3 mg and 0.6 mg) of laquinimod…
- Trial name
- NCT00745615
- Testing
- Laquinimod
- Where
- 45 sites in Czechia, Germany and 7 more
- Volunteers
- 257 people
- Sponsor
- Teva Pharmaceutical Industries, Ltd.
Multiple Sclerosis
Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses
The primary objective is to assess the long-term safety of teriflunomide in multiple sclerosis subjects. The secondary objective is to assess the long-term efficacy.
- Trial name
- NCT00228163
- Testing
- teriflunomide (HMR1726)
- Where
- 16 sites in Canada, France
- Volunteers
- 147 people
- Sponsor
- Sanofi
Relapsing Remitting Multiple Sclerosis
Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis
The purpose of this study is to determine whether RNS60 is effective in the treatment of RR-MS compared to interferon beta-1a.
- Trial name
- NCT01714089
- Testing
- RNS60 125 ml, RNS60 250 ml, Interferon beta 1a
- Where
- United States
- Sponsor
- Revalesio Corporation
Multiple Sclerosis
A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis
Primary objective was to assess the effectiveness evaluated by the time to failure of two doses of teriflunomide in comparison to interferon beta-1a in participants with relapsing Multiple Sclerosis [MS].
- Trial name
- TENERE (NCT00883337)
- Testing
- Interferon β-1a, Teriflunomide
- Where
- 54 sites in Belgium, Canada and 11 more
- Volunteers
- 324 people
- Sponsor
- Sanofi
Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis
"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"
This protocol is part of a clinical study to evaluate efficacy and safety of multiple intravenous administrations of HB-adMSCs for the treatment of Multiple Sclerosis.
- Trial name
- MS (NCT06800404)
- Testing
- Autologous HB-adMSCs
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hope Biosciences Research Foundation
Relapsing Remitting Multiple Sclerosis
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
The MS pilot study will assess the safety and investigate the remyelinating effects of the SetPoint System (study device) in adult patients diagnosed with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT06796504
- Testing
- Implant Procedure, Disease-Modifying Therapies (DMTs), Active stimulation
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- SetPoint Medical Corporation
Multiple Sclerosis (MS), Relapsing-Remitting MS
Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease
This study intends to explore evolution of MSRV expression by analyzing the levels of MSRV transcripts in blood, as well as the levels of the MSRV-Env protein in serum of MS patients.
- Conditions
- Multiple Sclerosis (MS), Relapsing-Remitting MS, Primary Progressive MS, Secondary Progressive MS
- Trial name
- LOMBARD (NCT01804647)
- Testing
- No study treatments administered - blood draws only
- Where
- 4 sites in France, Spain and 1 more
- Volunteers
- 58 people
- Sponsor
- GeNeuro Innovation SAS
Relapsing Remitting Multiple Sclerosis
A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS
To establish a pharmacokinetic (PK) profile of BG00012, as measured by its primary metabolite, monomethyl fumarate (MMF), during a 24-hour dosing period in subjects with relapsing-remitting multiple sclerosis (RRMS), with a…
- Trial name
- NCT00837785
- Testing
- BG00012
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid [TT]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine [23-PPV] either unboosted or boosted…
- Trial name
- NCT02545868
- Testing
- 23-PPV, 13-PCV Booster, Influenza Vaccine
- Where
- 22 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Hoffmann-La Roche
Relapsing-Remitting Multiple Sclerosis
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy.
- Trial name
- SOSTOS (NCT05090371)
- Testing
- Ofatumumab, Disease modifying treatment (DMT)
- Where
- 43 sites in United States, Canada
- Volunteers
- 136 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-remitting
Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)
This is a 24-month, observational, prospective, multinational, multicenter study to determine the relationship between the relapse (percentage of relapse free subjects) and adherence in subjects diagnosed with RRMS treated with…
- Trial name
- ADHERQOL (NCT02394782)
- Testing
- RebiSmart®2.0, MSdialog™
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing-Remitting Multiple Sclerosis
An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis
The primary objective of the study is to assess the immunogenicity of Daclizumab High Yield Process (DAC HYP) 150 mg administered every 4 weeks by subcutaneous (SC) injection using the pre-filled syringe (PFS) in participants…
- Trial name
- OBSERVE (NCT01462318)
- Testing
- Midazolam, Caffeine, S-warfarin
- Where
- 19 sites in United States, Czechia and 2 more
- Volunteers
- 133 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.
This is a 24-week phase 1b, randomized, double-blind, placebo-controlled, parallel-group, multicenter safety study comparing the tolerance profile of olesoxime (495 mg, od) when administered on top of Interferon beta in patients…
- Trial name
- MSREPAIR (NCT01808885)
- Testing
- olesoxime (TRO19622)
- Where
- 3 sites in France
- Volunteers
- 44 people
- Sponsor
- Hoffmann-La Roche
Relapsing-remitting Multiple Sclerosis
A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303
The purpose of this study is to explore the cardiac pharmacodynamics, safety and tolerability of MT-1303 in healthy subjects.
- Trial name
- NCT02193217
- Testing
- MT-1303-Low, MT-1303-High, Fingolimod
- Where
- United Kingdom
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Multiple Sclerosis
Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS
This is a phase IIa study in which GA Depot 80 or 40mg is administered as an IM injection to subjects with RRMS at 4 week intervals for 52 weeks of treatment.
- Trial name
- NCT02212886
- Testing
- GA Depot 80 mg, GA Depot 40 mg
- Where
- 3 sites in Israel
- Volunteers
- 25 people
- Sponsor
- Mapi Pharma Ltd.
Multiple Sclerosis, Relapsing-Remitting
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
The purpose of this study was to establish the efficacy and safety of two different doses of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous interferon…
- Trial name
- CARE-MS II (NCT00548405)
- Testing
- Alemtuzumab 12 mg, Alemtuzumab 24 mg, Interferon beta-1a
- Where
- 191 sites in United States, Argentina and 21 more
- Volunteers
- 840 people
- Sponsor
- Genzyme, a Sanofi Company